Michael Trauner

Summary

Affiliation: Medical University of Graz
Country: Austria

Publications

  1. doi Fatty liver and lipotoxicity
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Biochim Biophys Acta 1801:299-310. 2010
  2. ncbi Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University, Graz, Austria
    J Clin Gastroenterol 39:S111-24. 2005
  3. doi Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Wien Med Wochenschr 158:542-8. 2008
  4. pmc Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
    Anna Baghdasaryan
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Gut 59:521-30. 2010
  5. doi Bile acids as regulators of hepatic lipid and glucose metabolism
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Dig Dis 28:220-4. 2010
  6. doi New insights into autoimmune cholangitis through animal models
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Dig Dis 28:99-104. 2010
  7. ncbi Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Div of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, Graz A 8036, Austria
    Am J Physiol Gastrointest Liver Physiol 290:G923-32. 2006
  8. ncbi Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Am J Physiol Gastrointest Liver Physiol 289:G798-805. 2005
  9. ncbi Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Medicine, Karl Franzens University, Auenbruggerplatz 15, A 8036 Graz, Austria
    J Hepatol 39:480-8. 2003
  10. doi Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice
    Anna Baghdasaryan
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Laboratory of Experimental and Molecular Hepatology, Medical University, Graz, Austria
    Liver Int 28:948-58. 2008

Collaborators

Detail Information

Publications117 found, 100 shown here

  1. doi Fatty liver and lipotoxicity
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Biochim Biophys Acta 1801:299-310. 2010
    ..Therefore, the concept of hepatic lipotoxicity should be considered in future therapeutic concepts for fatty liver disease...
  2. ncbi Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University, Graz, Austria
    J Clin Gastroenterol 39:S111-24. 2005
    ..In addition, therapeutic strategies may be aimed at supporting and stimulating alternative detoxification pathways and elimination routes for bile salts in cholestasis...
  3. doi Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Wien Med Wochenschr 158:542-8. 2008
    ..Finally, drugs for the treatment of cholangiopathies may target bile toxicity via nuclear receptors (FXR, PPARalpha) regulating biliary phospholipid and bile acid excretion...
  4. pmc Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
    Anna Baghdasaryan
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Gut 59:521-30. 2010
    ..Curcumin, the yellow pigment of the spice turmeric, has pleiotropic actions and attenuates hepatic damage in animal models of chemically-induced liver injury. Whether curcumin has beneficial effects in cholangiopathies is unknown...
  5. doi Bile acids as regulators of hepatic lipid and glucose metabolism
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Dig Dis 28:220-4. 2010
    ..Collectively, these findings suggest that BA and targeting their receptor/signaling pathways may represent a promising approach to treat NAFLD and closely linked disorders such as obesity, diabetes, dyslipidemia and arteriosclerosis...
  6. doi New insights into autoimmune cholangitis through animal models
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Dig Dis 28:99-104. 2010
    ..These models have enhanced our understanding of the pathogenesis of PBC and PSC and will hopefully result in improved treatment of these disorders...
  7. ncbi Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Div of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, Graz A 8036, Austria
    Am J Physiol Gastrointest Liver Physiol 290:G923-32. 2006
    ..The induction of bile acid hydroxylation and Mrp4 was independent of FXR but could not counteract liver toxicity sufficiently. Limited effects of UDCA on Ost-alpha/Ost-beta may jeopardize its therapeutic efficacy...
  8. ncbi Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Am J Physiol Gastrointest Liver Physiol 289:G798-805. 2005
    ....
  9. ncbi Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Medicine, Karl Franzens University, Auenbruggerplatz 15, A 8036 Graz, Austria
    J Hepatol 39:480-8. 2003
    ..Whether adaptive changes in ATP-binding cassette (ABC) transporter expression are stimulated by bile acids and their nuclear receptor FXR is unknown...
  10. doi Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice
    Anna Baghdasaryan
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Laboratory of Experimental and Molecular Hepatology, Medical University, Graz, Austria
    Liver Int 28:948-58. 2008
    ..We therefore aimed to test whether formation and hepatic retention of abnormal PC metabolites contribute to the pathogenesis of liver injury in Mdr2(-/-) mice...
  11. doi Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury
    Tarek Moustafa
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Gastroenterology 142:140-151.e12. 2012
    ..The liver controls central processes of lipid and bile acid homeostasis. We aimed to investigate whether alterations in lipid metabolism contribute to the pathogenesis of chronic cholestatic liver disease in mice...
  12. pmc Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Am J Pathol 168:410-22. 2006
    ..Thus, we demonstrate that LCA feeding in mice leads to segmental bile duct obstruction, destructive cholangitis, periductal fibrosis, and an adaptive transporter and metabolic enzyme response...
  13. pmc A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz, Austria
    Am J Pathol 171:525-36. 2007
    ..This model may be valuable to investigate the mechanisms of xenobiotic-induced chronic cholangiopathies and its sequels including biliary fibrosis...
  14. doi Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna A 1090, Austria
    AIDS 27:227-32. 2013
    ..No association between 25(OH)D levels and response to pegylated interferon α-2a/2b plus ribavirin (PEGIFN + RBV) has yet been reported for HIV-HCV coinfected patients...
  15. ncbi Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress
    Martin Wagner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Drug Metab Dispos 35:1694-9. 2007
    ..Induction of the adaptive transporter response after CBDL is independent of the degree of the inflammatory response. Rather, retention of biliary constituents may determine transporter expression in CBDL...
  16. ncbi Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Medicine, Karl Franzens University, Auenbruggerplatz 15, A 8036, Graz, Austria
    J Hepatol 38:717-27. 2003
    ....
  17. ncbi Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Liver Int 27:920-9. 2007
    ..We therefore investigated expression of genes for bile acid synthesis, detoxification and alternative basolateral export and regulatory nuclear factors in primary biliary cirrhosis (PBC)...
  18. doi Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Vienna HIV and Liver Study Group, Vienna, Austria
    Liver Int 34:69-77. 2014
    ..The aim of this study was to prospectively assess health-related quality of life (HRQL) and severity of fatigue before, during and after antiviral therapy in HIV/HCV co-infected patients...
  19. doi Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice
    Claudia D Fuchs
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Hepatology 56:270-80. 2012
    ..Phosphoinositide-3-kinase inhibitor-known to be involved in FA-derived ER stress and blocked by OA-was increased in TM-treated WT mice only. In line with this, in vitro OA protected hepatocytes from TM-induced ER stress...
  20. pmc Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Medical University Graz, Graz, Austria
    Am J Pathol 175:2392-405. 2009
    ..Since there is no FXR expression in HSCs and MFBs in liver fibrosis, our data indicate that these cells may not represent direct therapeutic targets for FXR ligands...
  21. doi Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice
    Jörg Jahnel
    Laboratory of Experimental and Molecular Hepatology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University Graz, Auenbruggerplatz 15, Graz, Austria
    Liver Int 29:1316-25. 2009
    ..We hypothesized that colitis induces changes in bile composition via inflammation-induced reduction of hepatobiliary transporter gene expression, ultimately resulting in cholestasis and bile duct injury...
  22. ncbi Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles
    Peter Fickert
    Department of Medicine, Karl Franzens University, Graz, Austria
    Gastroenterology 123:1238-51. 2002
    ..The effects of ursodeoxycholic acid (UDCA) in biliary obstruction are unclear. We aimed to determine the effects of UDCA in bile duct-ligated and in Mdr2 knockout (Mdr2(-/-)) mice with biliary strictures...
  23. doi von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis
    Monika Ferlitsch
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Hepatology 56:1439-47. 2012
    ..vWF-Ag equals Model for End-Stage Liver Disease (MELD) in mortality prediction (area under the curve [AUC] = 0.71 for vWF-Ag versus AUC = 0.65 for MELD; P = 0.2)...
  24. pmc The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of Graz, Graz, Austria
    Lab Invest 90:844-52. 2010
    ..Our data indicate that genetic loss of neither OPN nor TNFR(1) significantly effects on the pathogenesis of DDC-induced sclerosing cholangitis, ductular reaction and resulting biliary fibrosis...
  25. doi The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
    Hepatology 50:893-9. 2009
    ..However, loss of K8 significantly increased liver injury in response to toxic stress...
  26. ncbi CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice
    Martin Wagner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Hepatology 42:420-30. 2005
    ....
  27. pmc Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH)
    Pooja Jha
    Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Institute of Pathology, Medical University of Graz, Graz, Austria
    Biochim Biophys Acta 1842:959-70. 2014
    ..NAFLD activity score was increased in liver, while WAT showed no changes and BAT showed even reduced inflammation...
  28. ncbi Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure
    Vanessa Stadlbauer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    ASAIO J 53:187-93. 2007
    ..Although both devices eliminate total bile acids to a similar extent, clearance of individual bile acids is different, leading to a slight change of the bile acid profile toward hydrophobic bile acids during Prometheus treatments...
  29. ncbi 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice
    Peter Fickert
    Department of Medicine, Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Medical University Graz, Austria
    Gastroenterology 130:465-81. 2006
    ..Experiments were performed to test in such mice the therapeutic effects of 24-norUrsodeoxycholic acid, a C(23) homologue of ursodeoxycholic acid with 1 fewer methylene group in its side chain...
  30. doi Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice
    Peter Fickert
    Research Unit for Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Department of Pathology, Medical University of Graz, Graz, Austria
    Hepatology 58:2056-69. 2013
    ..Prefeeding of hydrophilic norursodeoxycholic acid inhibited renal tubular epithelial injury in CBDL mice. In addition, we provide evidence for renal tubular injury in cholestatic patients with cholemic nephropathy...
  31. ncbi Oncosis represents the main type of cell death in mouse models of cholestasis
    Peter Fickert
    Laboratory of Experimental Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University, Auenbruggerplatz 15, A 8036 Graz, Austria
    J Hepatol 42:378-85. 2005
    ..Since the mechanisms leading to hepatocyte death in cholestasis are not well defined, we aimed to obtain closer insights into the related pathogenetic principles...
  32. ncbi Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice
    Martin Wagner
    Department of Medicine, Karl Franzens University, Graz, Austria
    Gastroenterology 125:825-38. 2003
    ..We aimed to investigate the role of the nuclear bile acid receptor (farnesoid X receptor [FXR]) in mediating changes in ABC transporter expression and in determining liver injury...
  33. ncbi The keratin cytoskeleton in liver diseases
    Kurt Zatloukal
    Institute of Pathology, Medical University of Graz, A 8036 Graz, Austria
    J Pathol 204:367-76. 2004
    ..The functional relevance of keratins in human diseases has recently been underlined by the identification of mutations in keratin genes in patients with liver cirrhosis...
  34. ncbi Hepatobiliary transporter expression in human hepatocellular carcinoma
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Medicine, Medical University, Auenbruggerplatz 15, A 8036 Graz, Austria
    Liver Int 25:367-79. 2005
    ..Furthermore, we investigated expression of the major bile salt uptake system Na(+)/taurocholate cotransporter NTCP (SLC10A1), since bile salt-coupled chemotherapeutics were proposed to increase therapeutic drug enrichment in HCC...
  35. doi Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment
    Tatjana Stojakovic
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
    Atherosclerosis 209:178-83. 2010
    ..The aim of our study was to prospectively examine the efficacy of low-dose atorvastatin on cholestasis as well as cardiovascular risk markers such as dyslipidemia and vascular function in patients with PBC...
  36. doi Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia
    Pooja Jha
    Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Institute of Pathology, Medical University of Graz, Graz, Austria
    Hepatology 59:858-69. 2014
    ..Notably, liganding PPARα through fenofibrate attenuated hepatic inflammation in both MCD-fed and LPS-treated ATGL-KO mice. In contrast, mice lacking HSL had a phenotype similar to the WT mice on MCD and LPS challenge...
  37. ncbi Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid
    Tatjana Stojakovic
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
    Hepatology 46:776-84. 2007
    ..001). Precursors of cholesterol biosynthesis (lanosterol, desmosterol, lathosterol) showed a similar pattern. No changes in serum bile acid levels and composition were observed during treatment...
  38. doi Nuclear receptors in liver disease
    Martin Wagner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    Hepatology 53:1023-34. 2011
    ....
  39. ncbi Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice
    Peter Fickert
    Deparment of Medicine, Medical University, Graz, Austria
    Gastroenterology 127:261-74. 2004
    ....
  40. doi Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis
    Martin Wagner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Semin Liver Dis 30:160-77. 2010
    ..This review gives a comprehensive overview on bile acid transporters in the enterohepatic circulation and their adaptive changes in response to cholestasis as well as the regulatory networks underlying these adaptive mechanisms...
  41. ncbi Molecular mechanisms of cholestasis
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Wien Med Wochenschr 156:380-5. 2006
    ..Such future approaches could specifically target nuclear receptors thus restoring defective transporter expression and supporting hepatic defense mechanisms against toxic bile acids...
  42. pmc The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
    Bernhard Scheiner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    PLoS ONE 10:e0143429. 2015
    ..However, the role of PNPLA3 rs738409 SNP on liver fibrosis and steatosis, portal hypertension, and virological response in HIV/HCV coinfection remains unclear...
  43. pmc Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    J Hepatol 58:1201-8. 2013
    ..norUDCA choleretic effects may therefore raise safety concerns when used in cholangiopathies with biliary obstruction. We therefore aimed at comparing the effects of UDCA and norUDCA in clear-cut obstructive cholestasis...
  44. doi Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling
    Thomas Reiberger
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Liver Int 33:561-8. 2013
    ..We evaluated the effects of nebivolol, a third generation beta-blocker capable of increasing NO-bioavailability on portal pressure, and on splachnic and systemic haemodynamics in a cirrhotic portal hypertensive rat model...
  45. ncbi Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Austria, and Karolinska University Hospital Huddinge, Stockholm, Sweden
    Mol Pharm 3:231-51. 2006
    ..Therefore, additional therapeutic strategies such as targeted activation of nuclear receptors are needed to enhance the hepatic defense against toxic bile acids...
  46. doi Targeting nuclear bile acid receptors for liver disease
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Dig Dis 29:98-102. 2011
    ..This article will provide a brief overview on the role of BA-activated NRs in cholestatic and fatty liver disease...
  47. doi New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension
    Philipp Schwabl
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria
    Liver Int 35:381-90. 2015
    ....
  48. doi How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
    Florian Hucke
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, AKH and Medical University of Vienna, Austria
    J Hepatol 61:1287-96. 2014
    ..We aimed to establish an objective point score to guide the decision for the first treatment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC)...
  49. doi Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
    Thomas Reiberger
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Gut 62:1634-41. 2013
    ..Additional α-adrenergic blockade (as by carvedilol) may increase the number of patients with haemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≥ 20% or to values <12 mm Hg)...
  50. pmc Bile acid transporters and regulatory nuclear receptors in the liver and beyond
    Emina Halilbasic
    Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    J Hepatol 58:155-68. 2013
    ..Thus, pharmacological modification of BA transporters and their regulatory nuclear receptors opens novel treatment strategies for a wide range of disorders...
  51. doi A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin
    Thomas Reiberger
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Antivir Ther 17:1327-34. 2012
    ..Data on the influence of antiviral therapy with pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV) are limited...
  52. doi Hepatobiliary transporter expression and post-operative jaundice in patients undergoing partial hepatectomy
    Gerwin A Bernhardt
    Division of General Surgery, Department of Surgery, Medical University of Graz, Graz, Austria
    Liver Int 32:119-27. 2012
    ....
  53. pmc Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice
    Emina Halilbasic
    Laboratory of Experimental and Molecular Hepatology, Department of Gastroenterology and Hepatology, University Clinic of Internal Medicine, Medical University of Graz, Graz, Austria
    Hepatology 49:1972-81. 2009
    ..Expression of Mrp4, Cyp2b10, and Sult2a1 was increased by norUDCA and di norUDCA, but was unaffected by tauro- norUDCA...
  54. pmc Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output
    Anna Baghdasaryan
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Hepatology 54:1303-12. 2011
    ..In addition, INT-767 dramatically reduced bile acid synthesis via the induction of ileal Fgf15 and hepatic Shp gene expression, thus resulting in significantly reduced biliary bile acid output in Mdr2(-/-) mice...
  55. ncbi Bilirubin kinetic modeling for quantification of extracorporeal liver support
    Aleksandra Jung
    Institut of Physiology, Center for Physiological Medicine, Medical University of Graz, Graz, Austria
    Blood Purif 24:413-22. 2006
    ..To provide a measure of treatment dose for extracorporeal liver support (ELS)...
  56. ncbi MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes
    Michael Trauner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    Semin Liver Dis 27:77-98. 2007
    ..Several drugs for the treatment of cholestatic liver diseases target MDR3 expression and function, further underscoring the clinical significance of this transport system...
  57. pmc ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1
    Guenter Haemmerle
    Institute of Molecular Biosciences, University of Graz, Graz, Austria
    Nat Med 17:1076-85. 2011
    ..These findings reveal a potential treatment for the excessive cardiac lipid accumulation and often-lethal cardiomyopathy in people with neutral lipid storage disease, a disease marked by reduced or absent ATGL activity...
  58. doi Coagulation parameters and major bleeding in critically ill patients with cirrhosis
    Andreas Drolz
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Hepatology 64:556-68. 2016
    ..One-year mortality in cirrhosis patients with and without major bleeding was 89% and 68%, respectively (P < 0.05 between groups)...
  59. doi DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting
    Sandra Beinhardt
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Transpl Int 29:999-1007. 2016
    ..Treatment with DAA combinations in renally impaired HCV patients is highly effective and well tolerated. These findings call for further controlled trials and data from real-life cohorts. ..
  60. doi Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, 1090, Vienna, Austria
    Wien Klin Wochenschr 128:414-20. 2016
    ..We aimed to evaluate the concept of treatment intensification with boceprevir (BOC) in HIV-positive patients with HCV-genotype 1 AHC (HIV/AHC-GT1) at high risk for failure to pegylated interferon/ribavirin therapy (PEGIFN/RBV)...
  61. doi The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites
    Theresa Bucsics
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Liver Int 36:1649-1656. 2016
    ..Hepatorenal syndrome (HRS) represents a severe form of renal injury in cirrhotic patients with ascites in the absence of certain triggers...
  62. pmc Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    PLoS ONE 9:e110503. 2014
    ....
  63. doi The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE
    Florian Hucke
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, AKH and Medical University of Vienna, Austria
    J Hepatol 60:118-26. 2014
    ....
  64. pmc Nuclear receptors as drug targets in cholestatic liver diseases
    Emina Halilbasic
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Clin Liver Dis 17:161-89. 2013
    ..They also control other pathophysiologic processes such as inflammation, fibrogenesis, and carcinogenesis involved in the pathogenesis and disease progression of cholestasis liver diseases...
  65. pmc Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice
    Indumathi Chennamsetty
    Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria
    J Lipid Res 53:2405-12. 2012
    ..In accordance, cAMP stimulated APOA transcription, and NA reduced hepatic cAMP levels. It is suggested that cAMP signaling might be involved in reducing APOA transcription, which leads to the lowering of plasma LPA...
  66. ncbi Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA
    Katrin Panzitt
    Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A 8036 Graz, Austria
    Gastroenterology 132:330-42. 2007
    ..We searched the human genome for novel genes including ncRNAs related to hepatocellular carcinoma (HCC)...
  67. doi Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Vienna HIV and Liver Study Group, Vienna, Austria
    Liver Int 35:876-85. 2015
    ....
  68. doi The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
    Wolfgang Sieghart
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, AKH and Medical University of Vienna, Austria
    Hepatology 57:2261-73. 2013
    ..011). These results were confirmed in the external validation cohort and remained significant irrespective of Child-Pugh stage and the presence of ascites prior the second TACE...
  69. doi Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease
    Csilla Putz-Bankuti
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
    Liver Int 32:845-51. 2012
    ..Previous studies suggest that chronic liver disease may be related to vitamin D deficiency. It is, however, not known whether 25(OH)D levels are associated with incident hepatic decompensation and mortality in chronic liver failure...
  70. doi Evolving concepts in primary sclerosing cholangitis
    Elisabeth Krones
    Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Liver Int 32:352-69. 2012
    ..Therefore, the aim of the current review is to summarize current and evolving pathophysiological concepts and to provide up-to-date perspectives including future treatment strategies for PSC...
  71. pmc Primary sclerosing cholangitis--the arteriosclerosis of the bile duct?
    Peter Fickert
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    Lipids Health Dis 6:3. 2007
    ..This hypothesis should stimulate translational research to facilitate the search for novel treatment strategies for both diseases...
  72. doi New molecular insights into the mechanisms of cholestasis
    Martin Wagner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Laboratory of Experimental and Molecular Hepatology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    J Hepatol 51:565-80. 2009
    ..This review will summarize the principles of molecular alterations in cholestasis and will give an overview of potential clinical implications...
  73. pmc Farnesoid X receptor represses hepatic human APOA gene expression
    Indumathi Chennamsetty
    Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Graz, Austria
    J Clin Invest 121:3724-34. 2011
    ..These findings may have important implications in the development of Lp(a)-lowering medications...
  74. doi Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease
    Thierry Claudel
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Austria
    Biochim Biophys Acta 1812:867-78. 2011
    ..Moreover, NRs may represent attractive drug targets for these disorders. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease...
  75. ncbi Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis
    Martin Wagner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Austria
    Ann Hepatol 4:77-99. 2005
    ....
  76. doi Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience
    Thomas Reiberger
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Waehringer Guertel 18 20, Vienna, Austria
    Wien Klin Wochenschr 124:395-402. 2012
    ..Recent studies suggest that TE may be used to screen for liver cirrhosis and clinically significant portal hypertension (≥ 10 mmHg; CSPH), whereas data on the clinical applicability of TE are limited...
  77. doi Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria michael trauner meduniwien ac at
    Dig Dis 30:39-47. 2012
    ..This article is a summary of an overview given at the 5th Falk Gastro Conference in Munich 2012 and reviews the challenges associated with diagnosis, surveillance and therapy of PSC...
  78. doi Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model
    Johannes Haybaeck
    Institute of Pathology, Medical University of Graz, Graz, Austria
    Lab Invest 92:857-67. 2012
    ..This stands in contrast to previous work where krt8⁻/⁻ and krt18⁻/⁻ mice on different genetic backgrounds were investigated...
  79. doi FGF19 signaling cascade suppresses APOA gene expression
    Indumathi Chennamsetty
    Institute of Molecular Biology and Biochemistry, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    Arterioscler Thromb Vasc Biol 32:1220-7. 2012
    ..Currently no safe drugs exists that lower elevated plasma lipoprotein(a) concentrations. We therefore focused on molecular mechanisms that influence apolipoprotein(a) (APOA) biosynthesis...
  80. pmc Nuclear receptors as therapeutic targets in cholestatic liver diseases
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Br J Pharmacol 156:7-27. 2009
    ..More specific and potent nuclear receptor ligands are currently being developed. This article will review the current knowledge on nuclear receptors and their potential role in the treatment of cholestatic liver diseases...
  81. doi Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis
    Rudolf E Stauber
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
    Liver Int 29:1516-20. 2009
    ....
  82. doi Ischemia and cholestasis: more than (just) the bile ducts!
    Martin Wagner
    Division of Gastroenterology and Hepatology, Medical University of Graz, Austria
    Transplantation 85:1083-5. 2008
  83. pmc Hepatotoxicity of NONI juice: report of two cases
    Vanessa Stadlbauer
    Department of Internal Medicine, Medical University Graz, Austria
    World J Gastroenterol 11:4758-60. 2005
    ..The most likely hepatotoxic components of Morinda citrifolia were anthraquinones. Physicians should be aware of potential hepatotoxicity of NONI juice...
  84. doi Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus
    Valentin Fuhrmann
    Department of Internal Medicine 3, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
    Liver Int 31:31-3. 2011
    ..Recent case series reported effective relief of pruritus using extracorporal liver support systems and plasmapheresis...
  85. ncbi Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male
    Csilla Putz-Bankuti
    Department of Internal Medicine, Medical University of Graz, Austria
    Wien Klin Wochenschr 118:769-75. 2006
  86. pmc Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia
    Adelheid Kratzer
    Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21 3, 8010 Graz, Austria
    J Lipid Res 50:312-26. 2009
    ..Our data provide evidence that DMHCA is a strong candidate as therapeutic agent for the treatment or prevention of atherosclerosis, circumventing the negative side effects of other LXR agonists...
  87. doi Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
    Gernot Zollner
    Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Pharmacol Ther 126:228-43. 2010
    ....
  88. ncbi Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Karl Franzens University, Graz, A 8036 Austria
    Am J Physiol Gastrointest Liver Physiol 282:G184-91. 2002
    ..These findings support the concept that downregulation of Ntcp in cholestasis limits intracytoplasmatic accumulation of potentially toxic bile acids...
  89. ncbi The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe
    Christina M Ambros-Rudolph
    Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, A 8036 Graz, Austria
    Arch Dermatol 143:757-62. 2007
    ....
  90. doi Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study
    Tatjana Stojakovic
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Atherosclerosis 208:564-71. 2010
    ..Serum gamma-glutamyl transferase (GGT) seems to be a predictor for coronary artery disease (CAD). The objective of this study was to elucidate the relationship between GGT and total as well as cardiovascular mortality...
  91. ncbi Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy
    Gerald C Gurakuqi
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
    Eur J Gastroenterol Hepatol 20:83-6. 2008
    ..Despite early intervention by angiography and embolization of an arteriobiliary fistula, the patient deteriorated and ultimately died due to multiorgan failure...
  92. ncbi In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation
    Peter Krisper
    Division of Nephrology and Hemodialysis, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 27, A 8036 Graz, Austria
    J Hepatol 43:451-7. 2005
    ....
  93. pmc Pathogenesis of primary sclerosing cholangitis
    Marion J Pollheimer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
    Best Pract Res Clin Gastroenterol 25:727-39. 2011
    ....
  94. ncbi Bile salt transporters: molecular characterization, function, and regulation
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Karl Franzens University, School of Medicine, Graz, Austria
    Physiol Rev 83:633-71. 2003
    ..This review is a comprehensive summary of current knowledge of the molecular characterization, function, and regulation of bile salt transporters in normal physiology and in cholestatic liver disease and liver regeneration...
  95. doi Adipose triglyceride lipase contributes to cancer-associated cachexia
    Suman K Das
    Institute of Pathology, Medical University of Graz, Graz, Austria
    Science 333:233-8. 2011
    ..Hsl-deficient mice with tumors were also protected although to a lesser degree. Thus, functional lipolysis is essential in the pathogenesis of CAC. Pharmacological inhibition of metabolic lipases may help prevent cachexia...
  96. doi Mechanisms of cholestasis
    Gernot Zollner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Laboratory of Experimental and Molecular Hepatology, Medical University of Graz, Auenbruggerplatz 15, A 8036 Graz, Austria
    Clin Liver Dis 12:1-26, vii. 2008
    ..In addition, current concepts regarding adaptive hepatocellular mechanisms counteracting cholestatic liver damage are discussed...
  97. ncbi Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis
    Herbert Tilg
    Department of Medicine, Division of Gastroenterology and Hepatology, University Hospital Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    J Hepatol 38:419-25. 2003
    ..Severe alcoholic hepatitis (AH) is associated with high mortality. Tumor necrosis factor-alpha (TNFalpha) has been demonstrated to play an important role in its pathophysiology...
  98. pmc Cytokeratins as targets for bile acid-induced toxicity
    Peter Fickert
    Department of Medicine, University of Graz, Auenbruggerplatz 25, A 8036 Graz, Austria
    Am J Pathol 160:491-9. 2002
    ..Thus, increased hepatocellular CK expression and phosphorylation in cholestasis may be caused by retention of toxic bile acids and reflect a hepatocellular stress response with potential beneficial effects...
  99. ncbi Molecular aspects of bile formation and cholestasis
    Marco Arrese
    Departmento de Gastroenterologi a, Facultad de Medicina, Pontificia Universidad Catolica de Chile, Marcoleta 347, 8320000 Santiago, Chile
    Trends Mol Med 9:558-64. 2003
    ..Potential implications of this knowledge for the design of new therapies of cholestatic disorders are also discussed...
  100. ncbi Hepatic transport systems
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    J Gastroenterol Hepatol 17:S105-12. 2002
    ..Beyond these well defined diseases, functional impairments of transport proteins may predispose to non-genetic diseases ranging from intrahepatic cholestasis of pregnancy to neurodegenerative disorders including Alzheimer's disease...
  101. pmc Bile acid-induced Mallory body formation in drug-primed mouse liver
    Peter Fickert
    Department of Medicine, Karl Franzens University, Auenbruggerplatz 25, A 8036 Graz, Austria
    Am J Pathol 161:2019-26. 2002
    ..Furthermore, CBDL and CA feeding resulted in rapid neoformation of MBs in drug-primed mice. It is concluded that MB formation in cholestatic liver diseases may be triggered by the action of potentially toxic bile acids...